title: Molecular profiling in breast cancer.
abstract: Molecular profiling has provided biological evidence for the heterogeneity of breast cancer through the identification of intrinsic subtypes like Luminal A, Luminal B, HER2+/ER- and basal-like. It has also led to the development of clinically applicable gene expression-based prognostic panels like the Mammaprint and Oncotype Dx. The increasingly sophisticated understanding allowed by this and similar technology promises future individualized therapy.
authors.affiliation: GlaxoSmithKline, Research Triangle Park, NC, USA.
authors.forename: Shannon R
authors.initials: SR
authors.lastname: Morris
authors.forename: Lisa A
authors.initials: LA
authors.lastname: Carey
mesh_terms: D001943:Breast Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000473:pathology; D004273:DNA, Neoplasm / Q000235:genetics; D005260:Female; D020869:Gene Expression Profiling / Q000379:methods*; D006801:Humans; D011237:Predictive Value of Tests; D011379:Prognosis
chemical_list: D004273:DNA, Neoplasm